Revvity reported a 4% year-over-year increase in second-quarter revenues to $720.3 million, driven by growth in diagnostics and life sciences sectors. Diagnostics revenue rose 3% amid immunodiagnostics and reproductive health gains, while life sciences revenue increased 5% primarily through increased sales to pharma and biotech clients. The company raised its full-year revenue guidance modestly but lowered earnings per share expectations. Despite tariff-related headwinds, Revvity has increased R&D spend by 11% and reduced SG&A expenses, signaling a focus on innovation and operational efficiency.